Evidence map›Paper›PMID 41359625›Full record

ArticlePLoS biology2025

Structures of G-protein coupled receptor HCAR3 in complex with selective agonists reveal the basis for ligand recognition and selectivity.

Fang Ye, Zhiyi Zhang, Binghao Zhang, Xinyu Li, Jiaxi Deng, Qian Miao, Peiruo Ning, Yunlin Chi, Geng Chen, Zhangsong Wu and 9 more

Abstract read
In one paragraph

Article in PLoS biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Fang YeGuangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, China.
Zhiyi ZhangKobilka Institute of Innovative Drug Discovery, The Second Affiliated Hospital, Shenzhen Futian Biomedical Innovation R&D Center, School of Medicine, Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Binghao ZhangKobilka Institute of Innovative Drug Discovery, The Second Affiliated Hospital, Shenzhen Futian Biomedical Innovation R&D Center, School of Medicine, Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Xinyu LiWarshel Institute for Computational Biology, School of Medicine, the Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Jiaxi DengGuangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, China.
Qian MiaoGuangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, China.
Peiruo NingKobilka Institute of Innovative Drug Discovery, The Second Affiliated Hospital, Shenzhen Futian Biomedical Innovation R&D Center, School of Medicine, Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Yunlin ChiKobilka Institute of Innovative Drug Discovery, The Second Affiliated Hospital, Shenzhen Futian Biomedical Innovation R&D Center, School of Medicine, Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Geng ChenKobilka Institute of Innovative Drug Discovery, The Second Affiliated Hospital, Shenzhen Futian Biomedical Innovation R&D Center, School of Medicine, Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Zhangsong WuKobilka Institute of Innovative Drug Discovery, The Second Affiliated Hospital, Shenzhen Futian Biomedical Innovation R&D Center, School of Medicine, Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Qian WangKobilka Institute of Innovative Drug Discovery, The Second Affiliated Hospital, Shenzhen Futian Biomedical Innovation R&D Center, School of Medicine, Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Lezhi XuKobilka Institute of Innovative Drug Discovery, The Second Affiliated Hospital, Shenzhen Futian Biomedical Innovation R&D Center, School of Medicine, Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Ningjie GongKobilka Institute of Innovative Drug Discovery, The Second Affiliated Hospital, Shenzhen Futian Biomedical Innovation R&D Center, School of Medicine, Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Bangning ChengWarshel Institute for Computational Biology, School of Medicine, the Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Zhigang MaKobilka Institute of Innovative Drug Discovery, The Second Affiliated Hospital, Shenzhen Futian Biomedical Innovation R&D Center, School of Medicine, Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Chungen QianDepartment of Reagent Research and Development, Shenzhen YHLO Biotech Co., Ltd., Shenzhen, Guangdong, China.
Lizhe ZhuWarshel Institute for Computational Biology, School of Medicine, the Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Xin PanDepartment of Cardiology, Central Laboratory, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China.
Yang DuKobilka Institute of Innovative Drug Discovery, The Second Affiliated Hospital, Shenzhen Futian Biomedical Innovation R&D Center, School of Medicine, Chinese University of Hong Kong, Shenzhen, Guangdong, China.ORCID 0000-0001-5115-0736

Funding

Guangxi UniversityNational Natural Science Foundation of ChinaNatural Science Foundation of GuangxiShenzhen-Hong Kong Cooperation Zone for Technology and InnovationShenzhen Sci. & Tech Innovation Bureau
6 · The paper itself

Abstract

The hydroxycarboxylic acid receptors (HCAR2 and HCAR3), also known as prototypical metabolite-sensing receptors, are key targets for treating dyslipidemia and metabolic disorders. While HCAR2 activation, but not HCAR3 activation, is associated with side effects of cutaneous flushing, the structural features and ligand preferences of HCAR3 remain less understood. Here, we used Sf9 cells to express HCAR3-Gi and HCAR2-Gi complexes, and present cryo-EM structures of HCAR3-Gi complexes with agonists compound 6O (3.31 Å), D-phenyllactic acid (3.05 Å), IBC293 (3.26 Å), and acifran (3.18Å), as well as HCAR2-Gi complex with agonist acifran (2.72 Å). Our findings reveal the mechanism behind 6O's highest affinity to HCAR3, attributed to its full occupation of both R1 and R2 regions of the orthosteric binding pocket. Moreover, combined with cAMP assay in HEK-293 cells, we have elucidated that the ligand selectivity between HCAR3 and HCAR2 depended on π-π interaction with F1073.32 (L1073.32 in HCAR2) and ligand-binding pocket size difference, facilitated by key residues difference V/L832.60, Y/N862.63, and S/W9123.48. Collectively, these structural insights lay the groundwork for developing HCAR3-specific drugs, potentially avoiding HCAR2-induced adverse effects.

Indexed as

Receptors, G-Protein-CoupledAnimalsBinding SitesCryoelectron MicroscopyCyclic AMPHEK293 CellsHumansLigandsProtein BindingSf9 CellsCyclic AMPHCAR2 protein, humanLigandsReceptors, G-Protein-Coupled

Identifiers

PMID41359625
PMCPMC12685177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.